10,300 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Parametrica Management Ltd

Parametrica Management Ltd bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 10,300 shares of the company’s stock, valued at approximately $249,000.

Other institutional investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. increased its position in Hims & Hers Health by 164.9% in the 3rd quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after acquiring an additional 32,108 shares during the period. Quest Partners LLC raised its position in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after acquiring an additional 807 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $1,064,000. Massachusetts Financial Services Co. MA bought a new position in shares of Hims & Hers Health in the 3rd quarter worth about $2,395,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of analyst reports. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Piper Sandler increased their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Truist Financial raised their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. Leerink Partners raised their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Finally, Citigroup reissued a “sell” rating and issued a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $37.31.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 23,287 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the sale, the insider now owns 209,661 shares of the company’s stock, valued at $7,193,468.91. The trade was a 10.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 4,213 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total value of $126,305.74. Following the transaction, the chief financial officer now directly owns 128,365 shares of the company’s stock, valued at $3,848,382.70. The trade was a 3.18 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 998,244 shares of company stock valued at $35,662,485 over the last quarter. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $37.06 on Wednesday. The stock has a 50-day moving average of $39.66 and a two-hundred day moving average of $29.22. The stock has a market cap of $8.23 billion, a P/E ratio of 84.23 and a beta of 1.37. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.